Article
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Circulation. Cardiovascular interventions - 1 Oct 2012
Sardella Gennaro, Calcagno Simone, Mancone Massimo, Palmirotta Raffaele, Lucisano Luigi, Canali Emanuele, Stio Rocco Edoardo, Pennacchi Mauro, Di Roma Angelo, Benedetti Giulia, Guadagni Fiorella, Biondi-Zoccai Giuseppe, Fedele Francesco
Abstract excerpt
BACKGROUND: High on-treatment platelet reactivity (HTPR) is associated with adverse outcomes. We aim to compare the novel thienopyridine prasugrel versus double-dose clopidogrel in patients with HTPR and explore the interaction between CYP2C19 genotype and both drugs. METHODS AND RESULTS: Consecutive stable patients undergoing percutaneous coronary intervention were screened with the Multiplate Analyzer P2Y12...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.